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recommendationA B S T R A C TVaccination strategies are among the most successful and cost-effective public health strategies for
preventing disease and death. Until recently, most of the existing immunization programs targeted infants
and children younger than 5 years which have successfully resulted in reducing global infant and child
mortality. Adolescent immunization has been relatively neglected, leaving a quarter of world’s population
underimmunized and hence vulnerable to a number of preventable diseases. In recent years, a large number
of programs have been launched to increase the uptake of different vaccines in adolescents; however, the
recommended vaccination coverage among the adolescent population overall remains very low, especially
in low- and middle-income countries. Adolescent vaccination has received signiﬁcantly more attention
since the advent of the human papillomavirus (HPV) vaccine in 2006. However, only half of the adolescent
girls in the United States received a single dose of HPV vaccine while merely 43% and 33% received two and
three doses, respectively. We systematically reviewed literature published up to December 2014 and
included 23 studies on the effectiveness of interventions to improve immunization coverage among ado-
lescents. Moderate-quality evidence suggested an overall increase in vaccination coverage by 78% (relative
risk: 1.78; 95% conﬁdence interval: 1.41e2.23). Review ﬁndings suggest that interventions including
implementing vaccination requirement in school, sending reminders, and national permissive recom-
mendation for adolescent vaccination have the potential to improve immunization uptake. Strategies to
improve coverage for HPV vaccines resulted in a signiﬁcant decrease in the prevalence of HPV by 44% and
genital warts by 33%; however, the quality of evidence was low. Analysis from single studies with low- or
very lowequality evidence suggested signiﬁcant decrease in varicella deaths, measles incidence, rubella
susceptibility, and incidence of pertussis while the impact was nonsigniﬁcant for incidence of mumps with
their respective vaccines. Further rigorous evidence is needed to evaluate the effectiveness of strategies to
improve immunization uptake among adolescents from low- and middle-income countries.
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Key search terms included: Adolescent OR youth OR teen* AND immunizaƟon OR vaccine OR vaccinaƟon OR 
vaccine* AND HPV OR human papilloma virus OR MMR OR measles OR mumps OR rubella OR varicella OR zoster 
OR VZV OR tetanus OR diphtheria OR pertussis OR tdap OR meningococcal OR MCV
10274 papers idenƟfied 
1612 abstracts reviewed
51 full texts reviewed 
HPV n= 7 MulƟ-vaccine coverage 
n= 11
Measles n= 1, MMR n= 1, TDap n= 
1, Varicella n= 1, Rubella n= 1
23 papers reviewed 
IniƟal Ɵtle screening for 
appropriateness of topic
Abstracts evaluated against 
inclusion and exclusion 
Retrieval and review of full 
arƟcle against inclusion and 
exclusion
28 studies excluded:
In appropriate age group
Adolescent data not reported 
Figure 1. Search ﬂow diagram. MCV ¼ meningococcal conjugate vaccine; VZV ¼ varicella zoster vaccine.
J.K. Das et al. / Journal of Adolescent Health 59 (2016) S40eS48 S41Vaccination programs are among the most successful and
cost-effective public health strategies for preventing infections.
Until recently, most of the existing immunization programs
targeted infants and children younger than 5 years which have
successfully resulted in reducing global infant and child
mortality [1]. As a result, adolescent immunization has been
overshadowed, leaving a quarter of world’s population vulner-
able to a number of preventable diseases. Estimates suggest that
around 35 million American adolescents fail to receive at least
one recommended vaccine [2]. In 2012, only half of the adoles-
cent girls in the United States received a single dose of human
papillomavirus (HPV) vaccine while merely 43% and 33%
received two and three doses, respectively [3]. Missed vaccina-
tion opportunities for adolescent vaccination against tetanus,
diphtheria, pertussis (TDaP), tetravalent meningococcal conju-
gate vaccine, and HPV are also common in the United States since
adolescents are less likely to utilize preventive care [4].
Infectious and vaccine-preventable diseases disproportion-
ately affect the low- and middle-income countries (LMICs) and
disadvantaged populations in high-income countries (HICs).
There were an estimated 266,000 deaths from cervical cancer
worldwide in 2012, accounting for 7.5% of all female cancer
deaths, of which nearly 85% occurred in developing countries [5].
The worldwide prevalence of infection with HPV in women
without cervical abnormalities is 11%e12% with higher rates in
Sub-Saharan Africa (24%), Eastern Europe (21%), and Latin
America (16%) [6]. The proportion of invasive cervical cancer
cases is higher in the LMICs with a relatively higher mortality/
incidence ratio compared to the HICs [7,8]. In U.S. settings,
African-American girls were less likely to have either initiated or
completed the three-dose HPV vaccination series [9]. This
warrants an additional focus on adolescents from LMICs and
underprivileged populations in HICs as they also deserve a
healthy transition into adulthood.
The recommended immunization during adolescence by
the World Health Organization includes three doses ofhepatitis B (for high-risk groups if not previously immunized),
Td booster, one dose of rubella (adolescent girls and/or
childbearing-aged women if not previously vaccinated), and
two doses of HPV for females (9e14 years) and three doses
for those aged 15 years and above [10]. Low immunization
rates in adolescents have a wide array of implications: out-
breaks of vaccine-preventable diseases, negative effects on
quality of life, and increased disease associated costs. Impor-
tantly, low immunization rates establish reservoirs of disease
in adolescents that can affect others, including high-risk
infants, elderly persons, and persons with underlying medi-
cal conditions.
Adolescent vaccination is a growing topic that has received
signiﬁcantly more attention since the advent of the HPV vaccine
in 2006. In recent years, large number of programs have been
launched to increase the uptake of different vaccines in
adolescent populations; however, the recommended vaccina-
tion coverage among adolescents still remains low. These
changes reﬂect an increased emphasis on the importance of
adolescent immunization, but by themselves they will not suf-
ﬁciently increase awareness or immunization rates [1]. The
American Academy of Pediatrics suggests implementing one or
more of the strategies including reminder calls, prompts or
standing orders, strong provider recommendation, including all
recommended vaccination at every visit, provider feedback,
educating patients and their parents, addressing costs, and
setting up vaccination clinics to increase immunization
coverage in adolescents [11].
This article is part of a series of reviews conducted to
evaluate the effectiveness of potential interventions for
adolescent health and well-being. Detailed framework, meth-
odology, and other potential interventions have been discussed
in separate articles [12e18]. In this article, we systematically
reviewed published literature to ascertain the effectiveness of
interventions to improve immunization coverage among
adolescents.
Table 1
Characteristics of included studies
Study Study design Country Setting Intervention Target population Control Outcomes assessed
Measles
Zhuo et al. [21] Beforeeafter China Community Supplementary immunization
activities
All ages No supplementary
immunization activity
Incidence of measles
MMR
Ogbuanu et al. [22] Beforeeafter United States School Selective school-based
immunization
9e14 years No intervention Incidence of mumps
Varicella
Nguyen et al. [23] Beforeeafter United States Nationwide
vaccination
Universal childhood varicella
vaccination program
All ages (outcome
assessed for 10e19 years)
Before implementation of
childhood varicella
immunization
Number of deaths
caused by varicella
infection
TDaP
Quinn and McIntyre [24] Beforeeafter Australia School School-based delivery of TDaP 12e19 years Nonavailability of school-
based immunization
Incidence of pertussis
Rubella
Nelson et al. [25] Beforeeafter United States School Vaccination requirement in
school
Girls older than 10 years Before the vaccination
requirement
Rubella susceptibility
HPV
Baandrup et al. [26] Beforeeafter Denmark Countrywide
provision
Licensing and mass provision of
HPV as part of National HPV
Program
12e19 years Absence of nationwide HPV
availability
Incidence of genital
warts
Bauer et al. [27] Beforeeafter United States Countrywide
provision
Introduction population-level
administration of HPV
vaccine
<21 years Nonavailability of population-
level vaccination
Incidence of genital
warts
Markowitz et al. [28] Beforeeafter United States Countrywide
provision
Introduction of HPV vaccine
into routine immunization
schedule
14- to 24-year-old females HPV vaccine not included in
routine immunization
schedule
Prevalence of HPV
Mesher et al. [29] Beforeeafter England Countrywide
provision
Introduction of National HPV
Immunization Program
16- to 24-year-old females Nonavailability of population-
level vaccination
Prevalence of HPV
Musto et al. [30] Quasitrial Canada School and
community
Within schools vaccination
during Grades 1, 5, and 9
9- to 11- and 13- to
15-year-old females
Community-based vaccine
availability at local
community clinics by
appointment
Vaccine uptake
Read et al. [31] Beforeeafter Australia Clinic Introduction of National HPV
Vaccination Program
12- to 18-year-old females HPV vaccine not included in
national immunization
schedule
Incidence of genital
warts
Reiter et al. [32] Beforeeafter United States Nationwide
recommendation
National permissive
recommendation for HPV
vaccine
11- to 17-year-old males No recommendation Vaccine initiation
Multivaccine
Averhoff et al. [33] Beforeeafter United States School Vaccination requirement in
school
Fifth- through
eighth-grade students
Students not subject to the
requirement
Vaccine coverage
Bugenske et al. [34] Quasitrial United States School Vaccination requirement in
school
13e17 years Students not subject to the
requirement
Vaccine coverage
Carlson and Lewis [35] Beforeeafter Canada School Vaccination requirement in
school
Grades 7e13 Students not subject to the
requirement
Vaccine coverage
Fogarty et al. [36] Beforeeafter United States School Vaccination requirement in
school
Seventh-grade students No control Vaccine coverage
Harper and Murray [37] Quasitrial United States Clinic Clinic staff recommended
vaccine on every visit
11e18 years No recommendation Vaccine coverage
Kempe et al. [38] RCT United States School Recall reminders for
vaccination
Sixth-grade male students No recommendation Vaccine coverage
Kharbanda et al. [39] Beforeeafter United States Hospital Vaccination requirement in
school
11e14 years Students not subject to the
requirement
Vaccine coverage
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J.K. Das et al. / Journal of Adolescent Health 59 (2016) S40eS48 S43Methods
We reviewed all literature published up to December 2014 to
identify studies on interventions to improve vaccination
coverage. We did not restrict our search to any time limits or
geographical settings. For the purpose of this review, the
adolescent population was deﬁned as aged 11e19 years; how-
ever, since many studies targeted youth along with adolescents,
exceptions were made to include studies targeting adolescents
and youth. Based on the current recommended vaccines for ad-
olescents [19], search was conducted to identify studies focusing
on improving coverage for HPV; measles, mumps, rubella
(MMR); TDaP; meningococcal conjugate vaccine; and varicella
vaccines among adolescents and youth. Studies were excluded if
they targeted age groups other than adolescents and youth or did
not report segregated data for the age group of interest. Studies
were excluded if the intervention was aimed at comparing the
efﬁcacy/effectiveness of different vaccine preparations, assessing
changes in antibody titers in individual subjects, or comparing
various modes of delivering vaccines without control or baseline
data.
Our priority was to select existing randomized controlled
trials (RCTs), quasitrials, and beforeeafter studies in which the
intervention was directed toward the adolescent and youth and
reported immunization coverage outcomes. Search strategy was
developed using appropriate keywords, medical subject heading,
and free text terms. The following principal sources of electronic
reference libraries were searched to access the available data:
The Cochrane Library, Medline, PubMed, Popline, LILACS,
CINAHL, EMBASE, World Bank’s JOLIS search engine, CAB Ab-
stracts, British Library for Development Studies at IDS, the World
Health Organization regional databases, Google, and Google
Scholar. The titles and abstracts of all studies identiﬁed were
screened independently by two reviewers for relevance and
matched. Any disagreements on selection of studies between
these two primary abstractors were resolved by the third
reviewer. After retrieval of the full texts of all the studies that met
the inclusion/exclusion criteria, data from each study were
abstracted independently and in duplicate into a standardized
form. Studies that met the inclusion criteria were selected and
double data abstracted on a standardized abstraction sheet.
Quality assessment of the included RCTs was done according to
the Cochrane risk of bias assessment tool. We conducted a meta-
analysis for individual studies using the software Review Man-
ager, version 5.3 (Cochrane Collaboration, London, United
Kingdom). Pooled statistics were reported as the relative risk
(RR) for categorical variables and standard mean difference for
continuous variables between the experimental and control
groups with 95% conﬁdence intervals (CIs). A grade of “high,”
“moderate,” “low,” and “very low” was used for grading the
overall evidence indicating the strength of an effect on speciﬁc
health outcome according to the Grading of Recommendations
Assessment, Development and Evaluation criteria [20].
Results
Figure 1 describes the search ﬂow while characteristics of the
included studies are detailed in Table 1. The search yielded 10,274
titles across all databases that were screened for the purpose of
this review. Screening the relevant abstracts resulted in 51 full
texts that were further screened after which 23 studies were
included in this review [21e43], of which four were RCTs, three
Figure 2. Forest plot for the impact of strategies on vaccination coverage. IV ¼ inverse variance; MCV ¼ meningococcal conjugate vaccine; SE ¼ standard error.
J.K. Das et al. / Journal of Adolescent Health 59 (2016) S40eS48S44quasirandomized trials, and 16 beforeeafter studies. Of the 23
included studies, seven [26e29,31,32] focused on the HPV, 11
studies [33e43] implemented interventions to improve coverage
of multiple vaccines recommended for adolescents while mea-
sles [21], MMR [22], varicella [23], rubella [25], and TDaP [24]
vaccines were assessed in one study each. All the studies were
conducted in HICs of the United States, Canada, Australia,
Denmark, and England. Included studies mainly focused on
evaluating the impact of licensing andmass provision of vaccines
as a part of national-level vaccination program to increase pro-
vision and coverage of adolescent vaccination, availability of free
vaccines, implementing vaccination requirement before entry
into school, reminder letters, telephone calls, and training of
clinic staff on adolescent vaccines and strategies to improve
immunization rates. Target populations in all studies were ado-
lescents aged 11e19 years except three studies in the HPV vac-
cine category that targeted adolescents and youth till the age of
24 years.Moderate-quality evidence from 13 studies suggested an
overall increase in vaccination coverage by 78% (RR: 1.78; 95% CI:
1.41e2.23; Figure 2) [30,33e43]. Subgroup analysis suggests that
vaccination requirement in school, reminders, and national
permissive recommendation had a signiﬁcant impact on
improving coverage while clinic staff training showed a nonsig-
niﬁcant impact. Strategies to improve coverage for HPV vaccines
including countrywide provision and clinic-based delivery
resulted in a signiﬁcant decrease in the prevalence of HPV by 44%
(RR: .56; 95% CI: .38e.82; Figure 3) [28,29] and genital warts by
33% (RR: .66; 95% CI: .52e.84; Figure 4) [26,27,31]; however, the
quality of evidence was low. Since only one study each was
included for measles, mumps, pertussis, and varicella vaccines, it
was not possible to pool results. Analysis from single studies with
lowor very low quality suggested signiﬁcant decrease in varicella
deaths (RR: .74; 95% CI: .56e.98), measles incidence (RR: .12; 95%
CI: .03e.38), rubella susceptibility (RR: .27; 95% CI: .15e.46),
and incidence of pertussis (RR: .24; 95% CI: .16e.36) while the
Figure 3. Forest plot for the prevalence of HPV. IV ¼ inverse variance; SE ¼ standard error.
J.K. Das et al. / Journal of Adolescent Health 59 (2016) S40eS48 S45impact was nonsigniﬁcant for incidence of mumps (RR: .96; 95%
CI: .42e2.18).
The outcome quality was rated to be “moderate” for vaccine
coverage; “low” for the prevalence of HPV, genital warts, and
mump incidence; and “very low” for varicella deaths, measles
incidence, rubella susceptibility, and incidence of pertussis. The
outcome quality was downgraded due to nonrobust designs,
heterogeneity, and limited generalizability to HICs only. A
summary of quality of evidence is provided in Table 2.
Discussion
Our review ﬁndings suggest that strategies to increase HPV,
TDaP, MMR, and varicella vaccination uptake among adolescents
can signiﬁcantly improve the coverage for these vaccines.
Implementing vaccination requirement in school, sending
reminders, and national permissive recommendation for
adolescent vaccination has the potential to improve immuniza-
tion uptake. These interventions have also led to signiﬁcant
decline in the prevalence of HPV and genital warts; incidence of
measles and pertussis; rubella susceptibility; and varicella
deaths. However, these ﬁndings should be interpreted with
caution since these are from single studies with low or very low
quality. Furthermore, these studies capture the incremental
beneﬁts of vaccination of those who may have missed earlier
doses or failed to seroconvert to earlier doses since these
vaccines are usually given at younger ages.
All the included studies were conducted in HICs depicting
dearth of evidence evaluating the effectiveness of strategies to
improve immunization uptake among adolescent from LMICs.
This could also be attributable to the scope of review since our
review was restricted to strict inclusion and exclusion criteria,
and we did not include gray literature reporting various country
case studies. Furthermore, recent state mandatory vaccinationFigure 4. Forest plot for the prevalence of genital wand exception policies could also have affected the vaccination
coverage rates; however, these programs and policy in-
terventions do not lend themselves to intervention studies. One
of the limitations of the reviewwas that the search termswere in
English, and hence foreign language articles may not have been
identiﬁed. There is lack of rigorously designed studies since most
of the existing studies have utilized the pre- and post-
implementation data after the approval of vaccine legislation or
national launch of vaccination programwithout having a control
site. Only a single study each for MMR, TDaP, varicella, and
meningococcal vaccines were found, showing a lack of focus
evaluating the impact of uptake for vaccines other than HPV. This
highlights the need for further studies to assess the uptake and
delivery platforms to deliver these vaccines in adolescent pop-
ulation. Included studies targeted various overlapping adoles-
cent and youth age groups that might have led to variations in
the outcome effect.
Despite the high burden of infectious diseases and low
immunization coverage in LMICs, strategies to improve vaccine
coverage for adolescent age group are minimal. Although there
are existing data outlining what exists in LMICs for delivering
adolescent immunization, primarily through school-based
approaches; however, there are little data that have systemati-
cally been evaluated for the impact of strategies to increase
coverage [44]. Various countries’ case studies have documented
experiences from LMICs with existing school-based immuniza-
tion programs, for example, in Indonesia, Malaysia, Sri Lanka, and
Tunisia; however, they lack rigorous evaluations [45]. For HPV,
various national-level programs are in place especially in LMICs;
Bhutan is the ﬁrst LMIC to roll out a national HPV vaccination
program, followed by Rwanda and Uganda. These programs
suggest that vaccine uptake can be improved by providing
evidence-based education and outreach; however, experiences
in these countries underscore complex challenges and planningarts. IV ¼ inverse variance; SE ¼ standard error.
Table 2
Summary of ﬁndings for the effect of interventions for improving immunization coverage among adolescents
Quality assessment Summary of ﬁndings
Number of
studies
Design Limitations Consistency Directness Number of events RR (95% CI)
Generalizability to population
of interest
Generalizability to intervention
of interest
Intervention Control
Vaccine coverage: moderate outcome-speciﬁc quality of evidence
13 studies
(14 data
sets)
RCT, quasi, and
observational studies
Study designs not robust Twelve studies
suggest beneﬁt
All studies targeted adolescents
aged 11e19 years in
developed countries
Interventions included
vaccination requirement in
school, reminders, and
national permissive
recommendation
5,092 4,303 1.78 (1.41e2.23)
HPV prevalence: low outcome-speciﬁc quality of evidence
Two studies Observational studies Study designs not robust Both studies
suggest beneﬁt
Studies targeted adolescents
aged 14e24 years in
developed countries
Intervention included
introducing HPV vaccine into
routine immunization
499 554 .56 (.38e.82)
Incidence of genital warts: low outcome-speciﬁc quality of evidence
Three studies Observational studies Study designs not robust All three studies
suggest beneﬁt
All studies from developed
countries targeting
adolescents from age 12 to
21 years
All studies focused on increased
provision of HPV vaccine
through national HPV
programs
3,875 5,409 .66 (.52e.84)
Varicella deaths: very low outcome-speciﬁc quality of evidence
One Observational study Study design not robust Only one study Intervention targeted all age
groups in the United States,
outcomes reported for 10- to
19-year age group
Universal childhood varicella
vaccination program
77 104 .74 (.56e.98)
Mumps incidence: low outcome-speciﬁc quality of evidence
One Quasitrial No randomization (quasitrial) Only one study Adolescents 9e14 years in the
United States
School-based immunization 28 7 .96 (.42e2.21)
Pertussis incidence: very low outcome-speciﬁc quality of evidence
One Observational study Study design not robust Only one study Interventions targeted
adolescents 12e19 years in
Australia
School-based delivery of TDaP
vaccine
31 128 .24 (.16e.36)
Rubella susceptibility: very low outcome speciﬁc quality of evidence
One Observational study Study design not robust Only one study Interventions targeted
adolescent girls >10 years in
the United States
Vaccination requirement in
school
15 49 .27 (.15e.46)
Measles incidence: very low outcome-speciﬁc quality of evidence
One Observational study Study design not robust Only one study Interventions targeted all ages
in China
Supplementary immunization
activities
3 26 .12 (.03e.38)
CI ¼ conﬁdence interval; HPV ¼ human papillomavirus; RCT ¼ randomized controlled trial; RR ¼ relative risk; TDaP ¼ Tetanus, diphtheria, pertussis.
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J.K. Das et al. / Journal of Adolescent Health 59 (2016) S40eS48 S47to ensure sustainability [46]. The number of LMICs that have
introduced HPV vaccination is relatively low; however, the
coverage levels in these countries are relatively higher than in
some HIC. Enabling factors for improved coverage in LMICs
include political will, nationwide sensitization campaign, school-
based vaccination, and community involvement [44e47].
Despite the availability of the HPV vaccine in HICs like the
United States, the uptake remains low. Vaccine utilization is a
multifactorial phenomenon which depends on several factors
including vaccine acceptability, perceived disease susceptibility,
perceived beneﬁt of vaccination, and intention to receive the
particular vaccine. A recent systematic review on barriers to HPV
vaccination among adolescents in the United States suggests
ﬁnancial concerns and parental attitudes as barriers to HPV
vaccination [48,49]. Good understanding and knowledge of the
factors and importance of vaccine in target population are
important for tailoring vaccine improvement strategies and
subsequent success of the program in achieving targeted vaccine
coverage [50]. It is imperative to develop and test context-
speciﬁc strategies to improve adolescent vaccine uptake and
dose completion rates. Educational interventions could increase
knowledge and clear misconceptions related to seriousness of
vaccine-preventable infection and cervical cancer, susceptibility
of adolescents to infection, and risk of infection. Such strategies
would also address barriers to adolescent vaccine uptake and
dose completion, such as parental concerns about vaccine safety,
and effectiveness [51]. Very few of the included studies in our
review utilized mHealth/eHealth technology for improving
immunization coverage which could be one of the potentially
effective strategies to target adolescent age group especially in
LMIC settings owing to the higher use in this age group and
recent explosion in Internet access in developing countries due
to the emergence of mobile Internet [52]. One of the concerns
with the introduction of HPV vaccine in low-resourced high-
burden countries is lack of cost-effective data; however, some
recent analysis suggests that HPV vaccination is likely to be
cost-effective, especially in LMICs [53,54].
Improving vaccination coverage to decrease the burden of
these preventable diseases would require an integrated
approach ranging from mass availability of vaccines at the
national level to targeting adolescents in school and during
health care visits to optimize the effectiveness of immuni-
zation programs. Besides these programs, there is a need for
an increased emphasis on the importance of adolescent im-
munization by identifying and overcoming barriers to
adolescent vaccination. Further research is needed to explore
why missed vaccination opportunities occur and to develop
evidence-based strategies to reduce missed opportunities and
improve adolescent vaccination coverage.Acknowledgments
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